Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
Chemical Quantum Images
The LouRoe
One in Ten Thousand
Periodic Tabloid
Chemical Musings
C&E News Blog
Chemiotics II
Noel O'Blog
In Vivo Blog
Chirality
BBSRC/Douglas Kell
Drug Discovery Opinion
The Chemblog
Realizations in Biostatistics
Heterocyclic Chemistry Blog
Molecule of the Day
Chemjobber
WSJ Health Blog
PK/PD
Social Detritus
ChemSpider Blog
Node in the Noosphere
Pharmagossip
Organometallic Current
Useful Chemistry
Great Molecular Crapshoot
No Name No Slogan
Post Doc Ergo Propter Doc
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Chemical Sabbatical
Totally Synthetic
Molecular Philosophy
Zusammen
Pharma's Cutting Edge
My Chemical Journey
The F- Blog
Chemical Professionals
Generally Chemistry
Chemistry World Blog
Eigenfunction/Eigenvalue
Synthesizing Ideas
Carbon-Based Curiosities
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Peter Murray-Rust
Chemical Forums
Depth-First
Curly Arrow
ChemCafe
Power of Goo
Fetz the Chemist
Carbon Tet
Chemical Crosspatch
Sceptical Chymist
Atomchuxky
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa
Making Graphite Work
Realm of Organic Synthesis
Liquid Carbon
Pharma Blog Review


Science Blogs and News:
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Getting Hired as a PhD | Main | ASCO Fever »

May 11, 2005

Public Utility, You Say?

Email This Entry

Posted by Derek

I wanted to return to that idea of Merck (and the other drug companies) settling into a role as a "regulated public utility." You can find calls for that sort of thing (in Marcia Angell's writings, for example), and there seem to be people who find the whole idea really appealing.

Me, I find it disgusting. And I don't even know which part of the idea I find most revolting. Is it the thought of working for a pharmaceutical version of the Post Office, with what would surely be a dynamic risk-taking culture? Is it the thought of waiting. . .waiting. . .while higher and higher bureaucratic commissions and review boards grind slowly on to tell us what we should work on next?

Or is it just that the idea is so unworkable that I feel pity for a person who advocates it? Look, electricity and water are utilities. Rail service can be treated as one (and doesn't Amtrak do a fine job at it?) But these are mature industries whose task is to deliver steady amounts of known goods. The drug industry doesn't fit any of those criteria.

We argue about what diseases to treat, and how to attack them. We argue about which drugs to try, and how to use them. We disagree about the best ways to start finding the drugs in the first place. We don't even understand many of our therapeutic targets that well, and there are many others that we haven't even heard of yet. Different populations need our products in completely different ways at different times, and vary widely in their ability (not to mention their willingness) to pay for them. Does this sound like a good candidate for public utility theory?

Only if you imagine a big machine, grinding away and producing grey blocks of something called "Health Care." It all reminds me of what someone said about Woodrow Wilson, that he had the most abstract mind the speaker had ever encountered. A normal person might watch a train go by and see a train, he said. Wilson, though, saw Transportation.

Comments (4) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. David Govett on May 12, 2005 2:27 PM writes...

Who wants to work for a regulated utility? Where's the adventure? Where's the profit? Feh!

Permalink to Comment

2. Brendan on May 15, 2005 4:50 PM writes...

No idea if this is feasible, or even advisable, but ...
What if you separated the creative / value-added side (drug discovery) from the more efficiency & reliability-focused side (drug production and marketing)?

This isn't far off of what the business model for the small biotechs is, although they keep drug production and farm out only marketing, in most cases. A better analogy would be the semiconductor world where there are capital-intensive contract manufacturers and creative semiconductor design firms. This idea seems to work there.

Any thoughts on this?

Permalink to Comment

3. weirdo on May 15, 2005 8:27 PM writes...

Brendan,
Not really sure how that would lead to cheaper drugs. And, many pharma already do it that way (the drug discovery "company" is separate from the development and sales "companies", and taxed differently). The expensive part, the clinicals, is still the expensive part. (Contrast that with semiconductors!!!)
Something Congress and your average consumer still doesn't get. And if prices get controlled, there will be fewer and fewer companies willing to take the huge risk of clinical trials with the prospect of an ever shrinking return. Better off making tennis shoes.

Permalink to Comment

4. markm on May 21, 2005 10:56 AM writes...

A better analogy than the post office might be AT&T before the breakup. It provided good quality telephone service at a quite high price - and it took decades>/i> to deploy new technology across the country, even after it was proven.

Not quite the model someone waiting for a cure for his disease would like, eh?

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Dealing With Hedgehog Screening Results
Animal Rights, You Say?
Blogroll Update
Pharma's Return on Investment: Yikes
How A Real Drug Industry Project Meeting Goes
Ghostwriting
Just Give It to NIH
How Not To Do It: The Secret Patent Decoder Ring